Pfizer unveils new swine respiratory disease portfolio

 

 

Pfizer has unveiled its newly-expanded swine respiratory disease (SRD) portfolio at a meeting in the company's European headquarters in Paris.

 

The company now has one of the most comprehensive ranges of vaccines and leading anti-infectives for the prevention and treatment of common porcine diseases across the production cycle.

 

One of the key additions to the SRD portfolio has been the Suvaxyn range of Mycoplasma hyopneumoniae (M. hyo) vaccines, including Europe's only product that protects against both M. hyo and Haemophilus parasuis (HPS).

 

Market research also released at the meeting shows that preventing M. hyo is a top priority for producers, with 67% of respondents vaccinating for the disease. The majority of those surveyed (80%) have also added Circovirus to their vaccination schedule, rather than replacing M. hyo. In addition, three-quarters of producers used anti-infectives for respiratory disease, specifically for outbreaks but in some cases for prevention.

 

Paolo Doncecchi, Associate Director, Pfizer Swine Marketing, says the research demonstrates that producers want to remain flexible in the face of disease dynamics.

 

The importance of HPS infection was highlighted by leading German veterinarian, Dr Franz Lappe, who believes that the infection is easily under-estimated as a primary cause of respiratory disease.

 

Pfizer's Suvaxyn M. hyo+HPS vaccine is the only product of its kind allowing producers to protect their herds against HPS and M. hyo – two of the industry's most economically damaging diseases, Doncecchi said.